

Supporting online material for

## **An $^{18}\text{F}$ -Alanine Derivative Serves as An ASCT2 Marker for Cancer Imaging**

Hui Liu, Yuxiang Han, Jiyuan Li, Ming Qin, Qunfeng Fu, Chunhong Wang, Zhibo Liu

\*To whom correspondence should be addressed. E-mail: Z.Liu ([zbliu@pku.edu.cn](mailto:zbliu@pku.edu.cn)).

The PDF file include:

Fig. S1. Synthetic route of Ala-BF<sub>3</sub> and radiolabeling reaction.

Fig. S2.  $^1\text{H}$  NMR spectrum of Ala-BF<sub>3</sub> precursor (compound 1).

Fig. S3.  $^{19}\text{F}$  NMR spectrum of HPLC-purified Ala-BF<sub>3</sub> ( $\delta = -153.58$  ppm).

Fig. S4. The LC-MS spectrum of HPLC-purified Ala-BF<sub>3</sub>.

Fig. S5. In vitro stability assay of  $^{18}\text{F}$ -Ala-BF<sub>3</sub> in PBS.


Fig. S6. In vitro stability assay of  $^{18}\text{F}$ -Ala-BF<sub>3</sub> in FBS.

Fig. S7. Time–activity curves of bone and joint from female Nu/Nu mice bearing BGC-823 xenografts.

Fig. S8. High-resolution mass spectrum (HRMS) of Ala-BF<sub>3</sub>.


Fig. S9. HPLC analysis of enantiomeric purity of L-isomer of Ala-BF<sub>3</sub>.

Fig. S10. Competitive inhibition of BGC-823 cell uptake of  $^{18}\text{F}$ -Ala-BF<sub>3</sub>.




**Figure S1.** Synthetic route of Ala-BF<sub>3</sub> and radiolabeling reaction.

LH-01-035.1.1.1r  
phone number 18800195517  
Supervisor Liuzhibo




**Figure S2.** <sup>1</sup>H NMR spectrum of Ala-BF<sub>3</sub> precursor (compound 1).


LH-20170309-01050-F. 10. 1. 1r




**Figure S3.**  $^{19}\text{F}$  NMR spectrum of HPLC-purified Ala- $\text{BF}_3$  ( $\delta = -153.58$  ppm).




**Figure S4.** The LC-MS spectrum of HPLC-purified Ala-BF<sub>3</sub>.




**Figure S5.** *In vitro* stability assay of  $^{18}\text{F}$ -Ala- $\text{BF}_3$  in PBS. Radioactive TLC chromatography of Ala- $\text{BF}_3$  after incubation in PBS at 37 °C for 0, 30, 60 and 120 min, respectively. As presented, less than 5% of defluorination was found within 120 min, validating minor defluorination *in vitro*.




**Figure S6.** *In vitro* stability assay of  $^{18}\text{F}$ -Ala- $\text{BF}_3$  in FBS. Radioactive TLC chromatography of Ala- $\text{BF}_3$  after incubation in FBS at 37 °C for 0, 30, 60 and 120 min, respectively. As presented above, no more than 5% defluorination was observed within 120 min, validating that  $^{18}\text{F}$ -Ala- $\text{BF}_3$  exhibited good stability in FBS .




**Figure S7.** Time–activity curves of bone and joint from female Nu/Nu mice bearing BGC-823 xenografts. The data are from 10 min dynamic scans following intravenous injection of  $^{18}\text{F}$ -Ala- $\text{BF}_3$  (200  $\mu\text{Ci}$ /mouse).



**Figure S8.** High-resolution mass spectrum (HRMS) of Ala-BF<sub>3</sub>.



**Figure S9.** HPLC analysis of enantiomeric purity of L-isomer of Ala-BF<sub>3</sub>. Enantiomeric purity of each compound was analyzed on a CROWNPAK column using an elution solution of Acetonitrile:water = 95:5 at a flow rate of 0.2 ml/min.



**Figure S10.** Competitive inhibition of BGC-823 cell uptake of <sup>18</sup>F- Ala-BF<sub>3</sub>. Cells are incubated in sodium-free phosphate-buffered saline (PBS) buffer or co-incubated with other AAs at 25 mM for 50 min. As shown, the entry of <sup>18</sup>F- Ala-BF<sub>3</sub> is channel-specific and can be inhibited efficiently by the natural Alanine .